GL Pharm Tech Corp. (204840.KQ)
KOSDAQ · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩3,580 (+0.00%) as of
Key statistics
- Market cap
- 55.53B
- Dividend yield
- 0.00%
- 52-week range
- 3,300.00 – 6,555.00
- Beta
- 0.47
- Revenue (TTM)
- 38.21B
- Profit margin
- -0.28%
- Volume
- 31.98k
About GL Pharm Tech Corp.
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disease, transplantation, and other areas. In addition, the company engages in developing new molecule entity pipeline products for dry eye disease. Further, it provides Cabalin CR extended-release tablet and Jample Ibufen syrup for the nervous system and sensory organs; Gisoren tablets for individual organs, digestive system, and peptic ulcer drugs; and Genstring Troki for treating individual organs and digestive system, as well as oral use. GL Pharm Tech Corp. was founded in 2002 and is headquartered in Seongnam-si, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Seongnam-si, South Korea
- Employees
- 33
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.